97 related articles for article (PubMed ID: 29517576)
21. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
[TBL] [Abstract][Full Text] [Related]
22. Radioactivity of blood samples taken from thyroidectomized thyroid carcinoma patients after therapy with (131)I.
Larkin A; Millan E; Noz M; Wagner S; Friedman K; Blum M
Thyroid; 2011 Sep; 21(9):1009-12. PubMed ID: 21834682
[TBL] [Abstract][Full Text] [Related]
23. The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer.
Capoccetti F; Criscuoli B; Rossi G; Ferretti F; Manni C; Brianzoni E
Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):536-45. PubMed ID: 19910907
[TBL] [Abstract][Full Text] [Related]
24. Radiation dose to the testes after 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer.
Ceccarelli C; Battisti P; Gasperi M; Fantuzzi E; Pacini F; Gualdrini G; Pierantoni MC; Luciani A; Djokich D; Pinchera A
J Nucl Med; 1999 Oct; 40(10):1716-21. PubMed ID: 10520714
[TBL] [Abstract][Full Text] [Related]
25. Radiation dose assessments in radioiodine (131I) therapy. 1. The necessity for in vivo quantitation and dosimetry in the treatment of carcinoma of the thyroid.
Schlesinger T; Flower MA; McCready VR
Radiother Oncol; 1989 Jan; 14(1):35-41. PubMed ID: 2928556
[TBL] [Abstract][Full Text] [Related]
26. Prediction of iodine-131 biokinetics and radiation doses from therapy on the basis of tracer studies: an important question for therapy planning in nuclear medicine.
Willegaignon J; Pelissoni RA; Lima BC; Sapienza MT; Coura-Filho GB; Buchpiguel CA
Nucl Med Commun; 2016 May; 37(5):473-9. PubMed ID: 26671852
[TBL] [Abstract][Full Text] [Related]
27. Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging.
Jentzen W; Hoppenbrouwers J; van Leeuwen P; van der Velden D; van de Kolk R; Poeppel TD; Nagarajah J; Brandau W; Bockisch A; Rosenbaum-Krumme S
J Nucl Med; 2014 Nov; 55(11):1759-65. PubMed ID: 25332440
[TBL] [Abstract][Full Text] [Related]
28. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
Eschner W; Kobe C; Schicha H
Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
[TBL] [Abstract][Full Text] [Related]
29. Utility of the radioiodine whole-body retention at 48 hours for modifying empiric activity of 131-iodine for the treatment of metastatic well-differentiated thyroid carcinoma.
Van Nostrand D; Atkins F; Moreau S; Aiken M; Kulkarni K; Wu JS; Burman KD; Wartofsky L
Thyroid; 2009 Oct; 19(10):1093-8. PubMed ID: 19732012
[TBL] [Abstract][Full Text] [Related]
30. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
Menzel C; Grünwald F; Schomburg A; Palmedo H; Bender H; Späth G; Biersack HJ
J Nucl Med; 1996 Sep; 37(9):1496-503. PubMed ID: 8790201
[TBL] [Abstract][Full Text] [Related]
31. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma.
Hänscheid H; Lassmann M; Luster M; Kloos RT; Reiners C
Endocr Relat Cancer; 2009 Dec; 16(4):1283-9. PubMed ID: 19628649
[TBL] [Abstract][Full Text] [Related]
32. 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact.
Freudenberg LS; Jentzen W; Görges R; Petrich T; Marlowe RJ; Knust J; Bockisch A
Nuklearmedizin; 2007; 46(4):121-8. PubMed ID: 17690789
[TBL] [Abstract][Full Text] [Related]
33. I-131 activities as high as safely administrable (AHASA) for the treatment of children and adolescents with advanced differentiated thyroid cancer.
Verburg FA; Biko J; Diessl S; Demidchik Y; Drozd V; Rivkees SA; Reiners C; Hänscheid H
J Clin Endocrinol Metab; 2011 Aug; 96(8):E1268-71. PubMed ID: 21613356
[TBL] [Abstract][Full Text] [Related]
34. Usefulness of 124I PET/CT imaging to predict absorbed doses in patients affected by metastatic thyroid cancer and treated with 131I.
Pettinato C; Monari F; Nanni C; Allegri V; Marcatili S; Civollani S; Cima S; Spezi E; Mazzarotto R; Fanti S
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):509-14. PubMed ID: 23358403
[TBL] [Abstract][Full Text] [Related]
35. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic 123I and 131I activities and radioiodine therapy. Effects on urinary iodine excretion in patients with differentiated thyroid carcinoma.
Meller B; von Hof K; Genina E; Deisting W; Meller J; Richter E; Baehre M
Nuklearmedizin; 2005; 44(6):243-8. PubMed ID: 16400384
[TBL] [Abstract][Full Text] [Related]
37. Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome.
Logue JP; Tsang RW; Brierley JD; Simpson WJ
Br J Radiol; 1994 Nov; 67(803):1127-31. PubMed ID: 7820407
[TBL] [Abstract][Full Text] [Related]
38. 124I PET Assessment of Response of Bone Metastases to Initial Radioiodine Treatment of Differentiated Thyroid Cancer.
Jentzen W; Verschure F; van Zon A; van de Kolk R; Wierts R; Schmitz J; Bockisch A; Binse I
J Nucl Med; 2016 Oct; 57(10):1499-1504. PubMed ID: 27199362
[TBL] [Abstract][Full Text] [Related]
39. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
[TBL] [Abstract][Full Text] [Related]
40. Why should the radioiodine dose be different in patients with differentiated thyroid carcinoma prepared with recombinant human TSH?
Pitoia F; Degrossi OJ; Niepomniszcze H
Eur J Nucl Med Mol Imaging; 2004 Jun; 31(6):924; author reply 924-5. PubMed ID: 15034676
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]